Latest News and Press Releases

Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.

Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.

WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024.

Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024.

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

Arcutis today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.

Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement

These findings are the first to characterize the unique molecular profile of seborrheic dermatitis